Strategic Acquisition GenArraytion was acquired by Nephros, signaling potential access to broader distribution channels and customer bases in medical and water testing markets. Leverage this connection to explore cross-sell opportunities in filtration, pathogen detection, and environmental monitoring solutions.

Small Business Advantage With a lean team and revenue under one million, GenArraytion appears agile and open to flexible partnerships, channel programs, and co-development deals that accelerate time-to-market for new diagnostic assays and sequencing services.

Veteran-Owned Credibility As a veteran-owned SMB, GenArraytion may appeal to government, defense, or veteran-focused procurement programs. Position solutions that align with biodefense, epidemiology, and environmental monitoring to tap this sector.

MultiPath Capabilities Their real-time multiplex PCR, bead-based assays, and custom microarrays enable multi-pathogen detection and antimicrobial characterization. Target opportunities in clinical labs, food/water safety, and environmental surveillance requiring rapid, multiplex diagnostics.

Recent News Footprint The Nasdaq-noted acquisition history suggests potential interest from larger buyers seeking specialized diagnostic tech. Use this momentum to approach larger distributors, healthcare networks, and research labs seeking validated pathogen detection innovations.